Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs

Author： Armanini Decio   Sabbadin Chiara   Donà Gabriella   Clari Giulio   Bordin Luciana  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.15, Iss.7, 2014-05, pp. : 909-912

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing

By Hood Sue   Cannon John   Foo Roger   Brown Morris  

Clinical Medicine, Vol. 5, Iss. 1, 2005-01 ,pp. : 55-60

Royal College Of Physicians

Access to resources Recommend Favorite

The aldosterone receptor – new insights?

By Fuller Peter  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 3, 2006-03 ,pp. : 201-203

Informa Healthcare

Access to resources Recommend Favorite

Drug interactions with angiotensin receptor blockers

By Böhler Steffen   Pittrow David   Bramlage Peter   Kirch Wilhelm  

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 7-18

Informa Healthcare

Access to resources Recommend Favorite

Vascular benefits of angiotensin receptor blockers

By Voors   Adriaan A  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-06 ,pp. : 987-997

Informa Healthcare

Access to resources Recommend Favorite

Current status of inflammasome blockers as anti-inflammatory drugs

By López-Castejón Gloria   Pelegrín Pablo  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 995-1007

Informa Healthcare

Access to resources Recommend Favorite